In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

In 2019, the FDA approved Spravato, "a nasal spray derived from ketamine," for treating severe depression. "But that approval came with strict guardrails to ensure patient safety," added the Post ...

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

So SPRAVATO is indicated for treatment resistant depression. It is esketamine. It's a single enantiomer of ketamine. It's an intranasally administered compound. It was approved in 2019 for ...

The nasal variant of ketamine, esketamine, was developed by Johnson & Johnson Pharmaceuticals under the name brand Spravato; it’s the only type of ketamine approved by the FDA for treatment ...